Imperative Care Launches ADAPT 2.0 Study to Optimize Stroke Treatment Technique — Imperative Care, Inc.

Event summary

Imperative Care has initiated the ADAPT 2.0 Clinical Study, a prospective, multi-center trial evaluating its Zoom Stroke System for acute ischemic stroke treatment.
The study aims to enroll up to 750 patients across 50 U.S. sites, focusing on reperfusion success and procedural efficiency.
ADAPT 2.0 technique incorporates a 0.088” intracranial catheter and continuous dual aspiration technology.
Primary endpoints include excellent reperfusion rates (mTICI≥2c) and safety metrics like Embolization to New Territory (ENT).
Study co-led by key neurologists from Stony Brook Medicine, Mount Sinai, UT Health San Antonio, and University of South Florida.

The big picture

The ADAPT 2.0 study represents an evolution of thrombectomy techniques, building on the original ADAPT method that became standard care for acute ischemic stroke treatment. This systems approach aims to address procedural inefficiencies while potentially improving long-term patient outcomes. The focus on reducing procedure time aligns with emerging research suggesting it may be a stronger predictor of clinical success than first-pass effect.

What we're watching

Clinical Validation: Whether ADAPT 2.0 can demonstrate superior reperfusion outcomes compared to existing techniques.
Regulatory Pathway: The pace at which study results could support expanded indications or reimbursement approvals.
Competitive Positioning: How this technique differentiates Imperative Care from competitors in the stroke intervention space.